Indolent CD4+ CAR T-Cell Lymphoma after Cilta-cel CAR T-Cell Therapy.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 38865661.
- Also identified by DOI 10.1056/NEJMoa2401530.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Indolent CD4+ cytotoxic chimeric antigen receptor (CAR) T-cell lymphoma involving the small intestine was diagnosed in a patient who had previously received ciltacabtagene autoleucel (cilta-cel) CAR T-cell therapy for treatment of myeloma. Targeted messenger RNA sequencing revealed the presence of CAR gene product in tumor cells. Whole-genome sequencing of samples of tumor and peripheral blood identified a single lentiviral insertion site within the second intron of the <i>SSU72</i> gene. In addition, numerous genetic alterations that may have contributed to malignant transformation were identified in the tumor sample. (Funded by MedStar Georgetown University Hospital.).
Medical subject headings
- CD4-Positive T-Lymphocytes
- Immunotherapy, Adoptive
- Lymphoma, T-Cell
- Receptors, Chimeric Antigen
- Antineoplastic Agents, Immunological